Seiichi Hayato
5PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jan 24, 2025
Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors.Seiichi Hayato, Lora Hamuro, Toshio Shimizu
|Aug 29, 2024
Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease.Oneeb Majid, Youfang Cao, Brian A Willis
|Mar 26, 2024
Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).Oneeb Majid, Seiichi Hayato, Sree Harsha Sreerama Reddy
|Sep 27, 2022
Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.Seiichi Hayato, Osamu Takenaka, Sree Harsha Sreerama Reddy
|Sep 24, 2018
Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer.Seiichi Hayato, Robert Shumaker, Jim Ferry
Pageof 1
